Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 105 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Katsiki, Niki [Clear All Filters]
The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity..
Curr Vasc Pharmacol. 10(6), 781-91.
(2012). Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance..
J Clin Lipidol. 6(1), 93.
(2012). Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study..
Clin Appl Thromb Hemost. 18(1), 113-4.
(2012). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'..
Clin Cardiol. 35(5), 315; author reply 316-7.
(2012). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012).
(2012). Adipokines and vascular risk in type 2 diabetes mellitus..
Angiology. 62(8), 601-4.
(2011). Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance..
Circ J. 75(8), 2027; author reply 2028.
(2011). Current treatment for nonalcoholic fatty liver disease..
Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
(2011). The DEFINE study: a bright future for CETP inhibitors?.
Expert Opin Investig Drugs. 20(3), 311-4.
(2011). Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus..
Expert Opin Ther Targets. 15(4), 401-20.
(2011). Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study..
Open Cardiovasc Med J. 5, 136-47.
(2011). Ezetimibe and low density lipoprotein subfractions: an ongoing debate..
Curr Med Res Opin. 27(3), 693-5.
(2011). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011). IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?.
Ann Med. 43(4), 249-58.
(2011). Passive smoking: the democratic right of nonsmokers to survive..
Angiology. 62(7), 520-2.
(2011). Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus..
Expert Opin Pharmacother. 12(10), 1457-61.
(2011). Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study..
Am J Cardiovasc Dis. 1(1), 48-59.
(2011). Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011). Rectus sheath hematoma: a simplified emergency surgical approach..
Open Cardiovasc Med J. 5, 4-5.
(2011).